Session III: Diversity Maturity Model
Breakout Discussions
Maturity Models

What are they?

- A subjective, yet structured way to evaluate progress
- A holistic view of the major areas that are important for progress
- A breakdown of major areas into key elements that tend to be more practical and definable
- A set of levels that, while based on an overarching concept of attainment, are specifically defined for each key element.

Why use them?

- Provide a broad approach to the topic necessary for success
- Give practical ways to
  - Measure in the absence of hard metrics
  - Establish goals
  - Gain organizational buy-in

From: https://ctti-clinicaltrials.org/accelerating-evidence-generation-resources-for-implementing-a-qbd-approach-to-clinical-trials/
Diversity Maturity Model

Purpose:

- Provide a guide for research organizations to assess their current organizational infrastructure for increasing diversity in clinical trials, as well as to identify a desired future state

Meant to provide broad considerations, not technical details
Breakout Session Topics

Group 1: Scientific Disease Level Strategy

Group 2: Community & Patient Engagement

Group 3: Measurement of Impact
Maturity Model Breakout Sessions

3:05 p.m.: Topic introduction & opening general questions or comments on maturity model section

3:15 p.m. Discussion questions

3:50 Moderators will enter key points into Mentimeter survey

3:55 Return to main meeting for closing
Breakout Discussion
Key Points
Closing, Day 2 Preview

Thank you for your participation in Day 1!

Will incorporate today’s content & discussions to finalize breakout session topics on Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m.</td>
<td>Welcome</td>
<td></td>
</tr>
<tr>
<td>1:05 p.m.</td>
<td>Session III: Representation in U.S. Clinical Trials</td>
<td>Richardae Araojo and Kaveeta Vasisht</td>
</tr>
<tr>
<td>1:35 p.m.</td>
<td>Session IV: Review of Maturity Model</td>
<td></td>
</tr>
<tr>
<td>2:05 p.m.</td>
<td>Session V: Breakout Discussions</td>
<td></td>
</tr>
<tr>
<td>3:35 p.m.</td>
<td>Closing Comments &amp; Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
THANK YOU

sara.calvert@duke.edu

www.ctti-clinicaltrials.org